サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1345369

ゲノミクスの世界市場-2023年～2030年

Global Genomics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
ゲノミクスの世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界のゲノミクス市場は、2022年に279億米ドルに達し、2023-2030年の予測期間中にCAGR 18.7%で成長し、2030年には1,154億米ドルに達すると予測されています。

世界のゲノミクス市場は、近年大きな成長と変貌を遂げており、様々な要因がそのダイナミクスに影響を与えています。すべての生物のすべての遺伝子と機能要素の同定と特性解析に対する政府投資は、世界のゲノミクス市場を引き続き牽引し、押し上げると思われます。世界の産業界は、その影響の軽減にますます重点を置くようになっています。

健康におけるゲノミクスは、特定の分子メカニズムや、この分子情報と健康介入や環境要因の相互作用による疾患の特定を検討します。ゲノミクスはリアルタイムPCR、突然変異解析などに応用されています。同様に、北米がゲノミクス市場を独占しており、ゲノミクスの採用増加と技術進歩により最大の市場シェアを獲得しています。

研究活動の増加、ゲノミクスの導入増加、ゲノム検査・解析の需要増加、製薬開発へのゲノミクスの導入増加、個別化医療の需要増加、技術進歩などの要因により、予測期間中、世界のゲノミクス市場は牽引役となることが期待されます。

市場力学

医薬品開発におけるゲノミクスの採用増加が市場の成長を牽引すると予測

医薬品開発におけるゲノミクスの採用増加は、予測期間にわたってゲノミクス市場の成長を促進すると予想されます。米国国立衛生研究所（NIH）によると、ゲノミクスは医薬品開発を加速するツールとして20年以上前から利用されています。さまざまな概念的アプローチや技術が、薬理学的摂動による結果の予測だけでなく、標的同定、標的の優先順位付け、扱いやすさを支援しています。

多くのゲノミクスベース検査は、より良い方法で病気の理解と管理に利用されています。例えば、2022年11月16日、ゲノミクスベース研究・診断会社であるStrand Life Sciences社は、予防的ウェルネスのための新しいゲノミクスベース検査ライン、Strand Genomic Wellnessを発表しました。これは、個人が自分の病気をよりよく理解し、管理できるようにすることを目的としています。

さらに、ゲノミクスは、研究者が特定の疾患に関連する遺伝子変異や変異を研究することにより、潜在的な創薬標的を特定し、検証することを可能にします。このような研究知識は、製薬会社がゲノム医療によって特定の疾患の根本的な原因をターゲットとする、より正確な治療法を開発するのに役立ちます。

例えば、2022年9月29日、DNAシーケンシングとアレイベース技術の世界的リーダーであるイルミナ社は、ゲノム医療で可能なことの限界を押し広げ、より高速で、より強力で、より持続可能なシーケンシングを可能にする新しい生産規模のシーケンサーであるNovaSeq Xシリーズ（NovaSeq XおよびNovaSeq X Plus）の発売を発表しました。革新的な新技術を採用したNovaSeq X Plusは、従来のシーケンサーの2.5倍のスループット、年間2万以上の全ゲノムを生成することができ、ゲノム探索と臨床的洞察を大幅に加速し、疾病を理解し、最終的に患者の生活を変革します。

精密医療向け需要の増大も市場の成長を促進すると予想される

精密医療向け需要の増大は、予測期間中、ゲノム市場を牽引すると予想されます。ゲノミクスは精密医療を進展させ、患者の健康とウェルネスを向上させるのに役立ちます。精密医療により、ヘルスケアプロバイダーは各患者の遺伝子プロファイルに合わせた個別化治療法を開発することができます。精密医療にゲノミクスを活用することで、治療効果が向上し、副作用が軽減され、患者の転帰が改善されます。

例えば、2023年8月16日、デューク大学医療システム・医学部は、遺伝性疾患感受性をより深く理解するために、包括的なゲノムデータと臨床情報を統合するOneDukeGenと呼ばれる精密医療研究を開始しました。この研究では、同意を得たデューク大学患者10万人以上を調査に参加させることを目指しています。

さらに、腫瘍のゲノム・プロファイリングは、より良いがん治療に革命をもたらしました。遺伝子変異を理解することで、ゲノミクスは、個々の患者の遺伝子機能を測定する次世代技術を用いて、より効果的な治療法を開発するのに役立っています。これがさらに市場の成長を後押ししています。

例えば、2023年4月12日、精密医療企業のファンクション・オンコロジー社は、CRISPRを搭載した個別化機能ゲノミクス・プラットフォームを開発することで、標的がん治療の未来に革命を起こすことを目標に、ゲノミクス・プラットフォームを正式に立ち上げました。サンディエゴを拠点とするこの新興企業は、従来の遺伝子配列決定に頼るのではなく、個々の患者レベルで遺伝子機能を測定することにより、次世代の標的がん治療を推進することに取り組んでいます。

厳しい規制上の課題が市場の成長を妨げる

ゲノミクスに関連する厳しい規制上の課題が、予測期間中の市場成長の妨げになると予想されます。ゲノムデータは機密性が高く、非常に個人的なものです。欧州の一般データ保護規則（GDPR）や米国の医療保険の相互運用性と説明責任に関する法律（HIPAA）など、データのプライバシーとセキュリティを管理する規制では、不正アクセスを防止するために患者情報を保護するための厳格な遵守が義務付けられています。

さらに、規制基準は、ゲノミクスを利用した遺伝子検査手法や検査室のプロセスの品質と正確性も保証しています。これは、誤った医学的判断につながりかねない誤った結果や誤った解釈を避けるために極めて重要です。規制当局は、遺伝子検査を医療現場で使用する前に、その臨床的妥当性と有用性の証拠を求めることが多いです。これにより、検査が信頼性が高く実用的な情報を提供することが保証されます。

本レポートの詳細について- サンプル請求

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 医薬品開発におけるゲノミクスの採用増加
      • ゲノム検査と分析に対する需要の増加
    • 抑制要因
      • 厳しい規制課題
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ紛争分析
  • DMIの見解

第6章 COVID-19分析

第7章 用途・技術別

  • 機能ゲノミクス
    • トランスフェクション
    • リアルタイムPCR
    • RNA干渉
    • 突然変異解析
    • SNP解析
    • マイクロアレイ解析
  • エピゲノミクス
    • バイサルファイトシーケンス
    • クロマチン免疫沈降（CHIP &CHIP-Seq）
    • メチル化DNA免疫沈降（MEDIP）
    • 高分解能メルト（HRM）
    • クロマチンアクセシビリティアッセイ
    • マイクロアレイ解析
  • パスウェイ解析
    • ビーズベース解析
    • マイクロアレイ解析
    • リアルタイムPCR
    • プロテオミクスツール
  • バイオマーカー探索
    • 質量分析
    • リアルタイムPCR
    • マイクロアレイ解析
    • 統計解析
    • バイオインフォマティクス
    • DNAシーケンス
  • その他

第8章 製品・サービス別

  • 製品
    • 装置/システム/ソフトウェア
    • 消耗品・試薬
  • サービス
    • NGSベースサービス
  • コアゲノミクスサービス
  • バイオマーカー翻訳サービス
  • 計算機サービス
  • その他

第9章 エンドユーザー別

  • 臨床研究
  • 学術・政府機関
  • 病院・クリニック
  • 製薬・バイオテクノロジー企業
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • ロシア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Agilent Technologies
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Bio-Rad Laboratories, Inc.
  • BGI Genomics
  • Color Genomics, Inc
  • Danaher Corporation
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Illumina, Inc.
  • Myriad Genetics, Inc.

第13章 付録

目次
Product Code: BT1667

Market Overview

Global Genomics Market reached US$ 27.9 billion in 2022 and is expected to reach US$ 115.4 billion by 2030, growing with a CAGR of 18.7% during the forecast period 2023-2030.

The global genomics market witnessing significant growth and transformations in recent years, with various factors influencing its dynamics. Government investments in identifying and characterizing all the genes and functional elements of all organisms will continue to drive and boost the global genomics market. The global industry is placing increasing emphasis on reducing its impact.

Genomics in health examines the particular molecular mechanisms and the interplay of this molecular information and health interventions and environmental factors in the identification of the disease. Genomics is applied for real-time PCR, mutational analysis, and others. Similarly, North America dominates the genomics market, capturing the largest market share owing to the increased adoption of genomics and technological advancements.

Owing to the factors such as increasing research activities, increasing adoption of genomics, rising demand for genomic testing and analysis, increasing adoption of genomics for pharmaceutical developments, rising demand for personalized medicine, and technological advancements are expected to drive the global genomics market over the forecast period.

Market Dynamics

Increasing Adoption of Genomics in Pharmaceutical Developments is Expected to Drive the Growth of the Market

The increasing adoption of genomics in pharmaceutical developments is expected to drive the genomics market growth over the forecast period. According to the National Institute of Health (NIH), genomics has been used as a tool for accelerating drug development for over 20 years. Various conceptual approaches and techniques assist target identification, target prioritization, and tractability, as well as the prediction of outcomes from pharmacological perturbations.

Many genomic-based tests are used in the understanding and management of the disease in a better way. For instance, on November 16, 2022, Strand Life Sciences, genomics-based research and diagnostics company, launched a new line of genomic-based tests for preventive wellness, Strand Genomic Wellness. It aims to help individuals understand and manage their disease better.

Moreover, genomics also enables researchers to identify and validate potential drug targets by studying the genetic mutations and variations associated with particular diseases. This research knowledge helps pharmaceutical companies develop more precise therapies that target the underlying causes of specific diseases with genomic medicine.

For instance, on September 29, 2022, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the launch of the NovaSeq X Series (NovaSeq X and NovaSeq X Plus), new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year, 2.5 times the throughput of prior sequencers, greatly accelerating genomic discovery and clinical insights, to understand disease and ultimately transform patient lives.

Increasing Demand for Precision Medicine is Also Expected to Drive the Growth of the Market

The increasing demand for precision medicine is expected to drive the genomics market over the forecast period. Genomics helps in advancing precision medicine and improving patient health and wellness. Precision medicine allows healthcare providers to develop personalized treatment options which are specifically tailored to each patient's genetic profile. Using genomics in precision medicine improves treatment efficacy and reduces adverse effects, leading to better patient outcomes.

For instance, on August 16, 2023, the Duke University Health System and School of Medicine launched a precision medicine study called OneDukeGen that will integrate comprehensive genomic data and clinical information to foster a deeper understanding of hereditary disease susceptibilities. The study aims to recruit more than 100,000 consented Duke patients to participate in the research.*

Furthermore, genomic profiling of tumors has revolutionized the better cancer treatment. By understanding the genetic mutations, genomics helps to develop more effective treatment options by using the next generation technologies by measuring the gene function of individual patients. This further drives the growth of the market.

For instance, on April 12, 2023, Precision medicine company Function Oncology officially launched a genomics platform with the goal of revolutionizing the future of targeted cancer treatment by developing a CRISPR-powered, personalized functional genomics platform. Rather than relying on traditional gene sequencing, the San Diego-based startup is committed to advancing the next generation of targeted cancer treatments by measuring gene function at the level of individual patients.

Stringent Regulatory Challenges Will Hamper the Market's Growth

The stringent regulatory challenges associated with genomics are expected to hamper the growth of the market over the forecast period. The genomic data is highly sensitive and very personal. Regulations governing data privacy and security, such as the General Data Protection Regulation (GDPR) in Europe or the Health Insurance Portability and Accountability Act (HIPAA) in the United States, require strict adherence to safeguard the patient information to prevent the unauthorized access.

Additionally, regulatory standards also ensure the quality and accuracy of genetic testing methodologies and laboratory processes by using genomics. This is crucial to avoid false results and misinterpretations that could lead to incorrect medical decisions. Regulatory authorities often require evidence of the clinical validity and utility of genetic tests before they can be used in medical practice. This ensures that the tests provide reliable and actionable information.

For more details on this report - Request for Sample

Segment Analysis

The global genomics treatment market is segmented based on application & technology, Products and Services, End-user, and region.

Based on Application and Technology, the Functional Genomics Segment is Estimated to Contribute 34.3% to the Growth of the Global Market

The functional genomics segment is expected to hold the largest market share over the forecast period. Functional genomics explains how genes and intergenic segments of the genome contribute to different metabolic pathways (gene expression patterns). The main objective of functional genomics is to resolve how the individual segment of an organism work together to produce a particular phenotype Functional genomics allows researchers to concentrate on the molecular mechanisms by underlying various diseases mainly rare diseases.

For instance, according to the European Bioinformatics Institute, functional genomics focuses on the dynamic expression of gene products in a specific context at a specific developmental stage or during a disease. In functional genomics, current knowledge of gene function is used to develop a model linking genotype to phenotype.

Moreover, functional genomics also plays an important role in the process of identifying potential drug targets by understanding the drug interactions with the body's molecular processes. This process further helps in drug development and discovery by providing detailed insights into the drug's efficacy and potential side effects. Functional genomics also enables researchers to understand how genes interact within networks to drive specific outcomes.

Geographical Penetration

North America Accounted for Approximately 38.2% of the Market Share in 2022, Owing to the Increasing Adoption of Genomic and Technological Advancements

North America is expected to hold the largest market share over the forecast period owing to the increasing adoption of genomics and technological advancements. The region is very well known for its advanced healthcare infrastructure, which rapidly performs research activities by using genomics. Their wide adoption of genomics helps in the clinical practice for pharmaceutical developments and their research activities.

Moreover, North America is at the forefront of the development of technological advancements in genomics. Many major genomic players in the region are focussing on the development of technologically advanced genomic assays such as Next Generation Sequencing (NGS) based assays and more, further contributing to the market dominance in the region.

For instance, on April 12, 2023, Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced the launch of NEW CentoGenome, an enhanced Next Generation Sequencing (NGS)-based assay. Healthcare professionals can leverage NEW CentoGenome to provide more comprehensive diagnostic information, which could accelerate access to potential treatment options.

Competitive Landscape

The major global players in the genomics market include Agilent Technologies, Bio-Rad Laboratories, Inc., BGI Genomics, Color Genomics, Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche Ltd., GE Healthcare, Illumina, Inc., and Myriad Genetics, Inc., among others.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global genomics market. During the pandemic, many research activities related to drug developments using genomics have been temporarily postponed due to the redirected focus on the COVID-19 pandemic and its related restrictions.

With the onset of the pandemic in early 2020, the applications of genomics are most widely used in COVID-19 and other infectious disease diagnosis. Still, many infectious diseases are able to cure by the power of pathogen genomics. For instance, on May 20, 2023, WHO and its partners announced that they launched a global network to help protect people from infectious disease threats through the power of pathogen genomics.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials such as genomic components and technologies. Movement restrictions and border closures delayed shipments and caused transportation delays. Additionally, some countries faced shortages of genomic components due to disruptions in their supply chain networks.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global genomics market. The conflict disrupted the availability of the components and technologies due to supply chain disruption, which are used in genomics research and diagnostics, this further delays the research projects and the product developments.

By Application & Technology

  • Functional Genomics

Transfection

Real-Time PCR

RNA Interference

Mutational Analysis

SNP Analysis

Microarray Analysis

  • Epigenomics

Bisulfite Sequencing

Chromatin Immunoprecipitation (CHIP & CHIP-Seq)

Methylated DNA Immunoprecipitation (MEDIP)

High-Resolution Melt (HRM)

Chromatin Accessibility Assays

Microarray Analysis

  • Pathway Analysis

Bead-Based Analysis

Microarray Analysis

Real-Time PCR

Proteomics Tools

  • Biomarker Discovery

Mass Spectrometry

Real-Time PCR

Microarray Analysis

Statistical Analysis

Bioinformatics

DNA Sequencing

  • Others

By Products and Services

  • Products

Instruments/Systems/Software

Consumables & Reagents

  • Services

NGS-Based Services

Core Genomics Services

Biomarker Translation Services

Computational Services

Others

By End-User

  • Clinical Research
  • Academic & Government Institutes
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Others

By Region

  • North America

U.S.

Canada

Mexico

  • Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

  • South America

Brazil

Argentina

Rest of South America

  • Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

  • Middle East and Africa

Key Developments

  • On July 18, 2023, Genomic Vision, a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to announce the launch of its new service, HexaCard. HexaCard is an application of Genomic Vision's proprietary Molecular Combing Technology (MCT) that offers precise visualization and measurement of individual DNA molecules. HexaCard aims to consolidate multiple technologies used in assessing engineered genome modifications, offering a streamlined, one-stop-shop solution for the cell and gene therapy (CGT), and biomanufacturing industries. By combining six analytical parameters into a single assay, Genomic Vision's HexaCard service offers a range of advantages in bioproduction and CGT applications.
  • On July 12, 2023, Illumina, Inc. ILMN recently announced the launch of the latest version of DRAGEN software, DRAGEN 4.2, for analysis of next-generation sequencing (NGS) data. DRAGEN 4.2 is expected to expand accuracy combined with its flexibility and scalability to enable efficient workflows and extract meaningful insights from genomic data.
  • On April 25, 2023, Apollo Hospitals announced the expansion of the Apollo Genomics Institute with the launch of a new facility in Chennai. This is the third facility for the healthcare major, which already has genomic institutes in Mumbai and Delhi.
  • On September 29, 2022, Neogen Corporation launched the new Encompass platform for bovine genomic results management and visualization. This innovative new data management solution will allow Igenity customers to gain greater insight into their data and maximize the benefits of genomic testing.

DataM Intelligence Opinion:

According to the DataM Intelligence, the genomics market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increased adoption in various sectors including the pharmaceutical sector. Genomic testing and analysis plays a very crucial role in this market. Their wide applications and advanced technologies expected to drive the market in the coming years. The genomics also plays an important role for the development of personalized medicines. Moreover, applications of genomics in rare disease diagnosis helps to rise the market in upcoming years.

Why Purchase the Report?

  • To visualize the global genomics market segmentation based on application and technology, Products and Services, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of genomics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global genomics market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Application & Technology
  • 3.2. Snippet by Products and Services
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption of Genomics in Pharmaceutical Developments
      • 4.1.1.2. Increasing Demand for Genomic Testing and Analysis
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Challenges
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine Conflict Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Application & Technology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application & Technology
    • 7.1.2. Market Attractiveness Index, By Application & Technology
  • 7.2. Functional Genomics *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Transfection
    • 7.2.4. Real-Time PCR
    • 7.2.5. RNA Interference
    • 7.2.6. Mutational Analysis
    • 7.2.7. SNP Analysis
    • 7.2.8. Microarray Analysis
  • 7.3. Epigenomics
    • 7.3.1. Bisulfite Sequencing
    • 7.3.2. Chromatin Immunoprecipitation (CHIP & CHIP-Seq)
    • 7.3.3. Methylated DNA Immunoprecipitation (MEDIP)
    • 7.3.4. High-Resolution Melt (HRM)
    • 7.3.5. Chromatin Accessibility Assays
    • 7.3.6. Microarray Analysis
  • 7.4. Pathway Analysis
    • 7.4.1. Bead-Based Analysis
    • 7.4.2. Microarray Analysis
    • 7.4.3. Real-Time PCR
    • 7.4.4. Proteomics Tools
  • 7.5. Biomarker Discovery
    • 7.5.1. Mass Spectrometry
    • 7.5.2. Real-Time PCR
    • 7.5.3. Microarray Analysis
    • 7.5.4. Statistical Analysis
    • 7.5.5. Bioinformatics
    • 7.5.6. DNA Sequencing
  • 7.6. Others

8. By Products and Services

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
    • 8.1.2. Market Attractiveness Index, By Products and Services
  • 8.2. Products *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Instruments/Systems/Software
    • 8.2.4. Consumables & Reagents
  • 8.3. Services
    • 8.3.1. NGS-Based Services
    • 8.3.2. Introduction
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.4. Core Genomics Services
  • 8.5. Biomarker Translation Services
  • 8.6. Computational Services
  • 8.7. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Clinical Research
  • 9.3. Academic & Government Institutes
    • 9.3.1. Introduction
    • 9.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.4. Hospitals & Clinics
  • 9.5. Pharmaceutical & Biotechnology Companies
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application & Technology
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application & Technology
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Russia
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application & Technology
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application & Technology
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application & Technology
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products and Services
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Agilent Technologies *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Bio-Rad Laboratories, Inc.
  • 12.3. BGI Genomics
  • 12.4. Color Genomics, Inc
  • 12.5. Danaher Corporation
  • 12.6. Eurofins Scientific
  • 12.7. F. Hoffmann-La Roche Ltd
  • 12.8. GE Healthcare
  • 12.9. Illumina, Inc.
  • 12.10. Myriad Genetics, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us